MaxCyte, Inc.

MXCT

NASDAQHealthcareBiotechnology

在 GoAI 中打开

前收盘价

US$1.38

US$0.00 · 0.00%

8月21日 16:00 ET

盘前

US$1.36

−US$0.02 · -1.45%

8月24日 7:27 ET

盘中时间采用ET。市场数据可能有所延迟。

GoAI 研究快照

简明呈现最新可用的模型信息。

2026年7月10日

41/ 100

GoAI评分

Hold

Wait — insufficient conviction to act

估值

Fair Value

动量

Gaining

情绪

Mixed

风险韧性

High Risk

完整 GoAI 研究

继续查看更深入的依据、催化因素和风险。

查看完整研究

人工智能生成的上下文仅供参考，并非投资建议。

公司概况

公司网站

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

行业: Biotechnology
部门: Healthcare
总部: US
首席执行官: Maher Masoud
上市以来: 2021年7月29日
雇员: 91